Business Advisory Board

Edward L. Erickson: Mr. Erickson has extensive domestic and international managerial experience in diagnostics, therapeutics, genomics and life science research products, having served as president, CEO or a director of over a dozen private and public companies in these industries. Most recently Mr. Erickson was chairman of MDxHealth, S.A., a publicly-traded molecular diagnostics company. His top management experience includes leadership roles, including president, CEO and/or executive chairman, of several private medical products companies, including three venture-capital backed companies, Cholestech (diagnostics), DepoTech (pharmaceuticals/drug delivery) and Immunicon (diagnostics).  The latter companies successfully completed initial public offerings (IPOs) under his leadership. Mr. Erickson holds an MBA with high distinction from the Harvard Business School and B.S. and M.S. degrees in Mathematics from the Illinois Institute of Technology.  He did military service as an officer in the nuclear submarine force.

Terry Fadem: Mr. Fadem is Managing Director, Corporate Alliances at the School of Medicine of The University of Pennsylvania, where he is also a member of the core team for the Mack Center for Managing Technological Innovation at the Wharton School. In addition, Mr. Fadem is the Director for the Commercialization and Entrepreneurship Core for the Institute for Translational Medicine and Therapeutics and serves on the Public Private Partnership Oversight Committee for the NIH Clinical Translational Science Award consortium of academic medical centers. He worked for the DuPont Company holding a number of business positions including Director, Corporate New Business Development. Mr. Fadem’s experience includes work in the non-profit sector as the former Scientific Director for the National Committee for Clinical Laboratory Standards (NCCLS) and most recently with the Biomedical Research and Education Foundation (BREF) where he is President. He is a frequent lecturer on managing innovation, new business development and negotiation at the School of Medicine and at the Wharton School of Business where he was a Senior Fellow in the Mack Center.

Dennis Fallen, MBA: Mr. Fallen is currently Vice President and General Manager of Fisher BioServices a division of Thermo Fisher Scientific, Inc. Fisher BioServices is the worlds largest biorepository services company, handling and storing biological specimens, stem cells, and biologic pharmaceutical intermediates. Mr. Fallen is co-founder and President and CEO of Transfusion Management Services, Inc. (TxMS). TxMS provides management and outsourcing services to hospitals for the operation of their blood banks and transfusion services. Prior to founding TxMS, he was Vice President, Business Development at Baxter Healthcare’s Biotech Group. Prior to Baxter, he was Vice President of the Plasma Therapeutics division at the American Red Cross Biomedical Services. Mr. Fallen’s responsibilities have included management, business development, marketing, sales and advertising for national healthcare associations and private companies. As a founder and partner in a healthcare consulting firm, he developed strategic market plans and developed and implemented packaged clinical programs for hospitals throughout the U.S. Mr. Fallen is experienced in therapeutic product manufacturing and has managed contract manufacturing relationships and R&D programs in both the US and Europe. He has managed clinical trial programs and new product launches of plasma protein based therapeutics. He holds B.S. and MBA degrees from DePaul University.

Noah J. Kroloff: Mr. Kroloff is a Partner at NGN Capital, a healthcare venture capital firm with $430 million under management and offices in New York and Heidelberg. 

Prior to joining NGN Capital, Mr. Kroloff, who has over 20 years experience in healthcare, served as an executive officer at i-STAT Corporation, a publicly-traded medical device company where he was Vice President for International Sales & Marketing and Corporate Development. He was actively involved in the sale of i-STAT to Abbott Laboratories for approximately $450 million. He also led the creation of a global alliance with Abbott, a $61 million alliance with Hewlett-Packard Medical Products Group and created i-STAT¹s international distribution network. Prior to i-STAT, Mr. Kroloff was an Engagement Manager at McKinsey & Co. where he advised leading pharmaceutical and diagnostic companies on R&D management, portfolio strategy, and alliance formation. Prior to his work in healthcare, he was a senior analyst at Fannie Mae. Mr. Kroloff received his BA in general science from Brandeis University and his MBA from the MIT Sloan School of Management, where he was a co-founder of and has served as a judge in the MIT $100K Entrepreneurship Competition. He is a member of the board of BeneChill and Coagulation Sciences, a board observer at Valtech Cardio and Cerapedics and is actively involved with OptiScan BioMedical and SpineView. 

He was served as a member of McKinsey’s alumni advisory council for 6 years.

David Lubarsky, MD, MBA: Since 2001, Dr. Lubarsky has served as the Emanuel M. Papper Professor and Chairman of the Department of Anesthesiology, Perioperative Medicine and Pain Management at the University of Miami Miller School of Medicine, running the largest anesthesia training program in the world at the country’s largest hospital. In 2006, he was additionally appointed as Senior Associate Dean for Safety, Quality and Risk Prevention and Assistant Vice President for Medical Administration for the University of Miami Health System. He is also a Professor in the Department of Management at the University of Miami School of Business, where he teaches about negotiations and incentive plans. Dr. Lubarsky has authored several books and over 100 peer-reviewed articles and book chapters. He is known for his contributions to the fields of healthcare economics, informatics, and systems/operating room management, and has won several awards and international renown for his research in these areas. He has had an active pharmaco-economics and medical marketing consulting practice, serving Abbott, Arkive, Aspect, Baxter, Docusys, Drager, Glaxo Smith Kline, Guilford, Hewlett-Packard, Infusion Dynamics, Organon, MGI, Pfizer, Picis, Roche and Somatogen among others.

Dr. Lubarsky served as tenured Professor and Vice Chair of Anesthesiology at Duke University Medical Center, where he led the division of general, vascular, and transplant anesthesia and critical care medicine before his departure at the end of 2001. While at Duke he worked closely with the office of technology transfer, and was active in developing business strategy of the Duke Healthcare system, and the physician group’s new business development. He taught several full term courses at Duke’s Fuqua School of Business and held an adjunct appointment at Fuqua from 2000 to 2002. 

Dr. Lubarsky earned his MD at Washington University, St. Louis, in the highly regarded Scholars Program in Medicine. He completed his residency, and his fellowship in Cardiac Anesthesia and Clinical Research, in the Department of Anesthesiology at New York University Medical Center. He received his M.B.A. in 1999 from the Fuqua School of Business at Duke University and was honored as a Fuqua Scholar.

Howard M. Schneider: Mr. Schneider has extensive management experience in the securities, commercial banking, and commodities markets, in the US and abroad. He served in numerous positions at Banker’s Trust, including Director of Investor Relations and as CEO of Metrosoft, Inc. He has served as an outside director, including audit committee chair, of public companies, and qualifies as a financial expert for Sarbanes-Oxley purposes. He has over 20 years experience testifying and lobbying before Congress and the executive branch. Mr. Schneider is currently Chair, Audit Committee, of Novelos Therapeutics (NVLT). He holds an AB from Harvard College in Economics and received his MBA with distinction from the New York University Graduate School of Business Administration.

Bruce Taragin: Mr. Taragin has 18 years of experience as a venture capital investor, entrepreneur, technology investment banker and corporate attorney. Prior to joining Blumberg Capital in 1998, where he is a Managing Director, Bruce co-founded and held several senior management positions within technology companies including Charles River Computers. Bruce also structured and managed early-stage technology transactions at Hambrecht & Quist, Mayer Brown & Platt and Bankers Trust Company. Bruce serves as a member or observer on the Board of Directors of DoubleVerify, CaseStack, Insightix, LiteScape, Correlix, Nolio, Revionics and Sweepery. He also serves on the board and the investment monitoring committee of the Jewish Community Foundation of Northern California. Bruce earned his BA in Finance and Communications, cum laude, from Yeshiva University, and his MBA and JD from Fordham University.

Terry Williams: Mr. Williams is a business consultant with extensive expertise in
development, approval, and commercialization of medical devices. He is
 Founder and CEO of a start-up medical device and software company that
 successfully designed, manufactured and received FDA approval on 3 clinical 
devices. His company also developed and received 5 US Patents with
 successful acute care product offerings to Kinetic Concepts (KCI), Genera l
Electric Medical Systems, Baxter Healthcare and Philips Medical Systems. He 
currently directs a medical device company that distributes negative
 pressure wound therapy devices and support surfaces for KCI.